Sector News

Transgene is shedding 120 jobs to save cash and get its pipeline moving

June 30, 2015
Life sciences
French biotech Transgene is planning to slash its payroll and redouble its focus on clinical development, moving on from a costly snub at the hands of Novartis.
 
The company will let go of about 120 employees as it steps away from vertical integration, cutting its losses in development and manufacturing with the goal of leaning on contractors to fill the void. With the resulting savings, Transgene plans to focus on R&D, investing in its pipeline of mid-stage treatments and laying out funds for translational research, the company said.
 
Transgene is also using the opportunity to rethink its approach to developing drugs, according to management, looking more to collaborations with academia and biopharma partners and vowing to consider deals at earlier stages of the process.
 
The change, which sent Transgene’s shares down about 14%, comes about a year after ex-partner Novartis decided against opting in on TG4010, a Phase II vaccine targeting lung cancer. The Swiss drugmaker’s decision nixed an agreement worth as much as $800 million, deflating Transgene’s market value in the process. The biotech has since promised to go it alone on a Phase III trial for TG4010 but is yet to begin enrollment.
 
Transgene has stressed that it will do everything it can to find new jobs for the employees affected by its latest cuts, working with top shareholder Institut Mérieux to place them. The company is “committed to by all means minimizing as much as possible the social impact of the restructuring plan,” management said in a statement, and the goal “is to leave no one without a solution.”
 
Meanwhile, Transgene and partner SillaJen are blueprinting a Phase III trial for Pexa-Vec, a vaccine for liver cancer that missed its main goal in Phase IIb. The partners got the FDA’s sign-off on their proposed study design in April and plan to enroll about 600 patients later this year. Transgene is also at work on earlier stage therapies for HPV-induced cancers, solid tumors, hepatitis B and tuberculosis.
 
By Damian Garde
 

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”